Cross-platform transcriptomic data integration identifies an overactive neuro-immune signature in human osteoarthritis synovium
Authors' conclusion
End-stage OA synovium is markedly enriched for neuroinflammatory and neuro-immune signaling, putatively governed by STAT1, FLI1, and VDR.
Study context
- Population
- Human non-OA and osteoarthritis (OA) synovium from eight publicly-available GEO datasets139 after quality control
- Participants
- 153 participants
- Comparison
- OA vs non-OA synovium
- Outcome
- Transcriptional phenotype of OA synovium, focused on pain-relevant signaling
Methodological detailsre-analysis of eight public GEO microarray and RNA-sequencing datasets, cross-platform statistical integration (weighted Z-test), single-cell RNA sequencing mapping, synovium-DRG ligand-receptor interactome
- Re-analysis of eight public GEO microarray and RNA-sequencing datasets
- Cross-platform statistical integration (weighted Z-test)
- Single-cell RNA sequencing mapping
- synovium-DRG ligand-receptor interactome
Main finding
As reported in the abstract
- Differentially-activated pathway terms in OA synovium, incl. strong enrichment for innate and adaptive immunity (notably MHC Class II) and extracellular matrix organization
- 276
- Genes driving neuro-immune signaling putatively governed by a STAT1, FLI1 and VDR regulatory network
- 27
- Predicted interactions between synovial cells and dorsal root ganglia (DRG) nociceptors
- 76
- Neuronal receptors involved
- 68
- Ligands overexpressed in OA synovium involved
- 32
Original publication
Cross-platform transcriptomic data integration identifies an overactive neuro-immune signature in human osteoarthritis synovium. Osteoarthritis Cartilage. Published 30 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →